Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
September 08 2020 - 4:05PM
Business Wire
- Presentations to be webcast on
www.exelixis.com -
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of
the company’s management team will participate in fireside chats at
the following virtual investor conferences in September:
- Morgan Stanley 18th Annual Global Healthcare Conference:
Exelixis is scheduled to present at 3:30pm EDT / 12:30pm PDT on
Tuesday, September 15, 2020.
- BofA Securities Global Healthcare Conference 2020: Exelixis is
scheduled to present at 5:35pm BST (British Summer Time) / 12:35pm
EDT / 9:35am PDT on Wednesday, September 16, 2020.
- Cantor 2020 Virtual Global Healthcare Conference: Exelixis is
scheduled to present at 4:40pm EDT / 1:40pm PDT on Wednesday,
September 16, 2020.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentations to ensure
adequate time for any software download that may be required to
listen to the webcasts. Replays will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery - all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized
companies. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005956/en/
Investors Contact: Varant Shirvanian Sr. Investor
Relations Manager Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024